![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
1-Phenethylbiguanide (DBI, phenformin) is an orally administered hypoglycemic agent which is not related to the sulfonylurea drugs.
DBI has been effective in treating diabetic subjects who require small amounts of insulin and as an adjunct to insulin therapy in the labile diabetic patient; however, the high incidence of gastrointestinal side effects it produces limits its use.
No systemic toxicity following administration of DBI has been noted in man.
The authors present their experience with DBI in treating 49 patients, and describe current theories concerning its mechanism of action.